Results 141 to 150 of about 3,855 (201)

The SGLT2 Inhibitor Dapagliflozin Disrupts the Cell Cycle at High Concentrations Without Altering Glycosphingolipid (De Novo)Biosynthesis. [PDF]

Int J Mol Sci
Jennemann R, Sandhoff R.
europepmc   +1 more source

Hospital Pharmacy [PDF]

, 2014
三村 泰彦, 加藤 敦, 友原 啓介, 小林 馨, 村崎 善之, 渡部 有貴, 窪田 佳代子, 足立 伊佐雄, 近岡 伸悟, 高木 昭佳   +9 more
core   +1 more source

Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-Pick disease type C (NPC): Presenting a rescored 4-domain NPC Clinical Severity Scale. [PDF]

Mol Genet Metab Rep
Mengel E, Patterson MC, Da Riol RM, Del Toro M, Deodato F, Gautschi M, Grunewald S, Grønborg SW, Harmatz P, Hennermann JB, Héron B, Maier EM, Roubertie A, Santra S, Tylki-Szymanska A, LaGorio L, Berry-Kravis E, Porter FD, Solomon B, Himmelstrup L, Mickle T, Guenther S, Dali CÍ.   +22 more
europepmc   +1 more source

Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions. [PDF]

Front Neurol
Li G.
europepmc   +1 more source

Exploring Small-Molecule Inhibitors of Glucosidase II: Advances, Challenges, and Therapeutic Potential in Cancer and Viral Infection. [PDF]

Int J Mol Sci
Oo TZM, Wuttiin Y, Choocheep K, Kumsaiyai W, Bunpo P, Cressey R.   +5 more
europepmc   +1 more source

Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease. [PDF]

Front Neurol
Byrne BJ, Parenti G, Schoser B, van der Ploeg AT, Do H, Fox B, Goldman M, Johnson FK, Kang J, Mehta N, Mondick J, Sheikh MO, Sitaraman Das S, Tuske S, Brudvig J, Weimer JM, Mozaffar T.   +16 more
europepmc   +1 more source

Evaluation of the safety and efficacy of miglustat for the treatment of Chinese patients with Niemann-Pick disease type C: A prospective, open-label, single-arm, phase IV trial. [PDF]

Intractable Rare Dis Res
Zhang H, Xiong H, Wei C, Yi M, Che Y, Zhuo J, Li X.   +6 more
europepmc   +1 more source

Pemphigus Vulgaris Autoantibodies Induce an Endoplasmic Reticulum Stress Response. [PDF]

J Invest Dermatol
Hoffman CL, Bharathan NK, Shibata Y, Giang W, Gudjonsson JE, Seykora JT, Prouty SM, Stahley SN, Payne AS, Kowalczyk AP.   +9 more
europepmc   +1 more source

Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease. [PDF]

Front Neurol
Byrne BJ, Parenti G, Schoser B, van der Ploeg AT, Do H, Fox B, Goldman M, Johnson FK, Kang J, Mehta N, Mondick J, Sheikh MO, Sitaraman Das S, Tuske S, Brudvig J, Weimer JM, Mozaffar T.   +16 more
europepmc   +1 more source